For the first time, the Food and Drug Administration (FDA) is allowing a cheaper knock-off of an expensive brand-name insulin to be substituted for the original.
This more affordable insulin called Semglee was first approved by the FDA in 2020 as a copycat of Sanofi’s basal insulin Lantus, taken as background long-acting insulin. In July 2021, Semglee became the first-ever to earn FDA’s
Made by Pharma companies Biocon and Viatris (formerly Mylan), Semglee is the first commercial injected insulin product developed by someone other than the “Big Three” insulin makers: Eli Lilly, Novo Nordisk, and Sanofi. This new interchangeable version of Semglee has been available since its launch in November 2021 at retail and mail-order pharmacies, and insurers have now started covering it in place of Lantus in their 2022 insurance plans.
Notably, Semglee is marketed as two-thirds less expensive than the list price of Sanofi’s Lantus. While this pricing may still be too high for many people, this marks a big moment for Americans with diabetes. It represents the fourth insulin manufacturer in the U.S. market with a dramatically lower-priced insulin that can be switched out easily, just like any generic drug. Observers believe this could shake up competition and potentially help lower insulin prices overall.
“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce healthcare costs,” said
- Semglee has been available under different product names in Europe and 45 other countries for several years, prior to FDA clearance.
- It is FDA-approved for adults with both type 1 and type 2 diabetes, and children with diabetes ages 6 to 15 years.
- It comes in U-100 concentration in the traditional 10mL glass vial (with 1,000 units), as well as 3mL prefilled insulin pens with one-unit dosing increments (as displayed on the pen’s white plunger that extends during dosing).
- The first version of Semglee was initially available in 2020, but the newer version that’s considered interchangeable with Lantus is a different product with new labeling. The first product has been available since November 2021.
- You may see the term “insulin glargine” and “
insulin glargine-yfgn” attached to the product, which is the official scientific lingo for this long-acting form of insulin that goes by different product names depending on who makes it.
- Semglee carries the same scientific indications and amino acid sequence as Lantus, so for all practical purposes, it is a lower-cost version of the same drug.
- Technically, Semglee is not a “generic,” but is officially considered a “follow-on” insulin, which basically means it’s a copy of an already-approved product.
- This is the second copycat of Lantus; the first was Eli Lilly’s Basaglar, approved by the FDA at year-end 2015.
You can find more specific information on the product website Semglee.com.
Yes, for all practical purposes, Semglee is equivalent to Lantus.
Unlike generic drugs, which share the exact same chemical composition as their pricier brand-name counterparts, biosimilar products like Semglee are “highly similar” duplicates of the reference brand name product (Lantus, in this case).
That is what the latest announcement by the FDA is all about.
“The interchangeable biosimilar product can be expected to produce the same clinical result as the reference product,” said
In a press call, Stein explained that Semglee may be substituted at the pharmacy without needing to get permission from a prescriber first, similar to how lower-cost generic drugs are often substituted.
The FDA officially defines a drug as interchangeable if it meets the following criteria:
- The drug is biosimilar to the reference product.
- It produces the same clinical result as the reference product in any given patient.
- There is no greater safety or diminished efficacy risk from switching between the interchangeable drug and the reference product.
In making this recent announcement, the FDA also released a series of
One of the most important aspects of Semglee entering the market is the potential effect on insulin pricing overall.
For reference, Sanofi’s Lantus clocks in at $283.56 for a single vial and $425.31 for a box of 5 pens.
Semglee costs significantly less, without any insurance factored in. There are four different versions of Semglee available, a move that allows Viatris to address both a lower-priced option as well as a higher-priced branded version that can be submitted to insurers for coverage.
Unbranded insulin glargine-yfgn
- $98.65 per 10mL vial
- $147.98 for a box of five 3mL pens
This list price (aka wholesale acquisition cost) of this unbranded version equates to three times less expensive than the list price of Sanofi’s Lantus, and about half the cost of Lilly’s Basaglar, which was the first Lantus copycat to be approved in late 2015.
At the time of FDA approval, Viatris told DiabetesMine that it priced Semglee at the level where Lantus pens started in 2007, and where those insulin vials were priced in 2010.
This lower-priced version of Semglee is interchangeable, aiming to help those who don’t have insurance or have high deductible insurance plans and need to pay cash for their necessary insulin.
- $269.38 per 10mL vial
- $404.04 per package of five 3mL pens
While the company hasn’t publicly acknowledged this, it seems clear that the move to have a “branded” version is to give Viatris a product they can submit to insurers and their Pharmacy Benefit Managers (PBMs) for coverage. It’s a bit of “have your cake and eat it, too” in that Viatris doesn’t want to give up money it makes from higher-priced insulins, but also wants to look good by helping those who need a more affordable option.
It’s worth noting that the main company behind Semglee is formerly known as Mylan, known for making the EpiPen, whose high prices prompted public outcry back in 2016. The company eventually caved and lowered the price for this allergy emergency rescue pen. It’s possible that as Viatris entered the insulin market, that past negative PR storm serves as inspiration to concentrate on low list prices.
Our Diabetes Community has been protesting skyrocketing insulin prices for many years now, with the #insulin4all movement gaining major steam. Some policy changes are happening at the state level, but big insulin makers have made only incremental “Band-Aid-type” improvements in offering narrow financial assistance programs. These programs are quite often not accessible to many people who need them most.
Pharma companies have stated they can’t just lower their list prices because that interferes with contracts and would make the insulin unaffordable to many who currently access it through their insurance plans and pharmacy benefits.
The fact is that list prices remain obscenely high for most insulins and this new Semglee is now breaking that streak. For the first time in over a decade (since the late 2000s), the United States has an insulin at a list price lower than $100.
Some believe Semglee’s price is still too high, in light of a 2018 study published in the BMJ Global Health journal that estimates the actual cost of insulin production.
Even at its lower price, Semglee’s manufacturers will follow the lead of other insulin makers offering financial assistance and discount programs to help those in need.
With this interchangeable designation, it’s going to become more important for pharmacists and people with diabetes to know their options before a prescription is filled.
Although the FDA now allows for pharmacy substitutions, there are differing state pharmacy laws in place. According to healthcare services giant Cardinal Health, that tracks this information, all 50 states and Washington D.C. have enacted laws for biologic interchangeability.
Prescribers can still write a prescription including language like “no substitutions allowed,” or that “brand name drug is medically necessary.” As state laws vary, this may or may not impact what the pharmacist can do in changing out insulin types. Also, some states require the pharmacist to notify the prescriber’s office as well as the patient, whereas other states don’t require this notification.
Only a handful of states do not directly allow for automatic pharmacy-level substitution, unless there is a note on the prescription that a substitution can be made. Meanwhile, a few other states have taken a more nuanced approach in only allowing those auto-substitutions if it results in a lower cost to the patient.
This interactive map has a breakdown of specific state laws on this issue throughout the United States.
Dr. Anne Peters of the University of Southern California (USC) Keck School of Medicine is pleased to hear about the interchangeability, and believes it can be a convenience for some who might otherwise struggle to afford high-priced insulin. However, she urges caution because switching insulin isn’t something everyone will be comfortable with — at least not without first talking to their prescribing doctor.
“There are patients, particularly those with type 1, who may feel there are differences between the brand name and the biosimilar and will not want this change, especially without a conversation with their doctor,” she said. “This new biosimilar could confuse some doctors; there will be a need for more education to stress that these two insulins are, in fact, the same.”
Peters also notes how despite Semglee and Lantus being clinically the same insulin, the actual insulin pens used to inject each liquid are slightly different. So, that may be a factor in deciding which of these insulins someone wants to use.
“I have long wished there was an interchangeability among insulin analogues, so it was easier for switching,” Peters said. “On the other hand, I have so many patients who get upset about switching, because they feel comfortable with what they are prescribed. This approval is good if it makes insulin less expensive and more accessible. I just want to make sure we do not limit patient choice.”
A glaring irony with this latest development is all the positive fanfare around the first time an insulin can be switched out, regardless of what the patient or prescribing doctor may want.
Advocates have long been pushing back against the practice of Non-Medical Switching, where an insurance company or those creating the insurance formularies decides to cover a different insulin (or other drug) and change it out without the consent of the patient or doctor.
For years, many people with diabetes have been suddenly forced to switch from one type of insulin to another, simply because the insurance companies have struck a better business deal.
At the Diabetes Patient Advocacy Coalition (DPAC), longtime diabetes advocate George Huntley who lives with T1D himself, said, “The interchangeable designation by the FDA means that it is truly a unit-for-unit identical reaction. From a non-medical switching standpoint, it’s essentially a generic equivalent unlike switching that occurs in other circumstances.”
He hopes this development can be used to reduce non-medical switching for medications that do not have the interchangeable designation.
“As advocates we should work to hold the interchangeable designation to the be the standard for switching a medication,” Huntley said. “The prescriber should prevail.”